Oral levofloxacin in the treatment of community-acquired pneumonia
Braz. j. infect. dis
;
4(2): 61-5, apr. 2000. tab
Article
in English
| LILACS
| ID: lil-278691
RESUMO
We evalueted the efficacy of oral levofloxacin (500mg/day for 7-21 days) in the treatment of adults patients with community-acquired pneumonia (CAP) requiring hospitalization in an open prospective stydy. The microbiological cause of the pneumonia was identified in 14/20 patients using lower respiractory tract secretions obtained by bronhoscopy (12) and/or blood culture (2). Eight patients has S.pneumoniae, 2 P.aeruginosa, 1 H.influenzae, 1 S.aureus, 1 mixed S.aureus and K.pneumoniae, and 1 E.coli and Grp.D Streptococcus. All of the patients evaluated were judged to be improved or cured. Levofloxacin is an additional option as monotherapy for the treatment of CAP.
Search on Google
Index:
LILACS (Americas)
Main subject:
Pseudomonas aeruginosa
/
Streptococcus pneumoniae
/
Ofloxacin
/
Gram-Positive Bacterial Infections
/
Gram-Negative Bacterial Infections
/
Community-Acquired Infections
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS